These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11900314)

  • 1. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.
    Wiholm BE
    Curr Med Res Opin; 2001; 17(3):210-6. PubMed ID: 11900314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
    Sommet A; Grolleau S; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Eur J Clin Pharmacol; 2008 Aug; 64(8):829-34. PubMed ID: 18509626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
    Lugardon S; Lapeyre-Mestre M; Montastruc JL
    Eur J Clin Pharmacol; 2004 Nov; 60(9):673-7. PubMed ID: 15517227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
    Durrieu G; Olivier P; Montastruc JL;
    Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM; Mosholder AD; Lu S
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib.
    Schoors D
    Clin Ther; 2002 Mar; 24(3):468-9; author reply 469-70. PubMed ID: 11952030
    [No Abstract]   [Full Text] [Related]  

  • 9. [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].
    Pedrós C; Cereza G; Laporte JR
    Med Clin (Barc); 2002 Mar; 118(11):415-7. PubMed ID: 11943104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal failure associated with the use of celecoxib and rofecoxib.
    Ahmad SR; Kortepeter C; Brinker A; Chen M; Beitz J
    Drug Saf; 2002; 25(7):537-44. PubMed ID: 12093311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A; Goldkind L; Bonnel R; Beitz J
    Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
    Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R; Ruzicka T; Grewe M
    Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of rofecoxib and celecoxib with warfarin.
    Schaefer MG; Plowman BK; Morreale AP; Egan M
    Am J Health Syst Pharm; 2003 Jul; 60(13):1319-23. PubMed ID: 12901032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
    Lee YH; Ji JD; Song GG
    Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.